ST. LOUIS, May 12, 2023 /PRNewswire/ -- Centene Corporation (NYSE: CNC) announced today it will present at the Bernstein 39th Annual Strategic Decisions Conference, to be held Wednesday, May 31-Friday, June 2, 2023, in New York City.
Centene will present on Thursday, June 1st at 9:00 a.m. Eastern Time (ET). A simultaneous live audio webcast is available at: https://kvgo.com/bernstein-2023-39th-annual-sdc/centene-corp-june.
A webcast replay will be available afterwards via the Company's website at www.centene.com, under the Investors section.
About Centene Corporation
Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. Centene offers affordable and high-quality products to nearly 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace, the TRICARE program. The Company also contracts with other healthcare and commercial organizations to provide a variety of specialty services focused on treating the whole person. Centene focuses on long-term growth and value creation as well as the development of its people, systems and capabilities so that it can better serve its members, providers, local communities, and government partners.
Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, http://investors.centene.com.
Last Trade: | US$36.82 |
Daily Change: | 1.08 3.02 |
Daily Volume: | 9,529,813 |
Market Cap: | US$18.080B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load